Flumazenil for the treatment of cocaine dependency

Details Flumazenil for the treatment of cocaine dependency Flumazenil for the treatment of cocaine dependency

2007-03-06

2007-03-06

Padmanabhan, Sreenivasan (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S220000

Reexamination Certificate

active

10622068

ABSTRACT:
The invention relates to the use of flumazenil to produce a medicament for the treatment of cocaine dependency. The flumazenil can be administered sequentially in small quantities at short intervals until a therapeutically effective quantity for the treatment of cocaine dependency has been administered.

REFERENCES:
patent: 5028611 (1991-07-01), Halikas
patent: 5229120 (1993-07-01), DeVincent
patent: 6346528 (2002-02-01), Yelle
patent: 6451783 (2002-09-01), Hadcock et al.
patent: 6455276 (2002-09-01), Le Bourdelles et al.
patent: 6740677 (2004-05-01), Xue et al.
Gasior et al. Chlormethiazole: Effectiveness against Toxic Effects of Cocaine in Mice. The Journal of Pharmacology and Experimental Therapeutics. vol. 295, No. 1, pp. 153-161. Oct. 2000.
Derlet, R.W. et al., Anticonvulsivant Modification of Cocaine-Induced Toxicity in the Rat, Neuropharmacology, 1990, vol. 29, No. 3, pp. 255-259.
Derlet, R.W. et al., Flumazenil Induces Seizures and Death in Mixed Cocaine-Diazepam Intoxications, Annals of Emergency Medicine, 1994, vol. 23, No. 3, pp. 494-498.
Malbrain, M.L. et al., A Massive, Near-Fatal Cocain Intoxication in a Body-Stuffer, Acta Clinica, Belgium, 1994, vol. 49, No. 1, pp. 12-18.
Uki, F. et al., The Effect of Flumazenil Administration on Acute Cocaine Intoxication of Rats, Arukoru Kenkyu to Yakubutzu Izon, 1994, vol. 29, No. 2, pp. 92-102.
Woolf, A., Cocaine Poisoning, Clinical Toxicology Review, May 1995, Vo. 18, No. 8.
Baldwin, H.A., et al., “Flumazenil Prevents the Development of Chlordiazepoxide Withdrawal in Rats Tested in the Social Interaction Test of Anxiety,”Psychopharmacology, vol. 97, No. 3, pp. 424-426 (1989) (Abstract Only).
Brooks-Kayal-A.R., et al., “Human Neuronal γ-Aminobutyric AcidAReceptors: Coordinated Subunit mRNA Expression and Functional Correlates in Individual Dentate Granule Cells,”J. Neuroscience, vol. 19, No. 19, pp. 8312-8318 (1999).
Criswell, H.E., et al., “Effect of Zolpidem on Gamma-aminobutyric Acid (GABA)-Induced Inhibition Predicts the Interaction of Ethanol with GABA on Individual Neurons in Several Rat Brain Regions,”J. Pharmacol. Exp. Therp., vol. 273, No. 1, pp. 526-536 (1995) (Abstract Only).
Ferrara, G., et al., “Increased Expression of the Neuropeptide Y receptor Y1 Gene in the Medical Amygdala of Transgenic Mice Induced by Long-term Treatment with Progesterone or Allopregnanolone,”J. Neurochemistry, vol. 79, pp. 417-425 (2001).
Frostholm, A., et al., “Harmaline-induced Changes in Gamma Aminobutyric AcidAReceptor Subunit mRNA Expression in Murine Olivocerebellar Nuclei,”Molecular Brain Research, vol. 85, pp. 200-208 (2000).
Gee, K., et al., “A Putative Receptor for Neurosteroids on the GABAAReceptor Complex: The Pharmacological Properites and Therapeutic Potential of Epalons,”Crit. Rev. Neurobiol, vol. 9, Nos. 2-3, pp. 207-227 (1995).
Gulinello, M., et al., “Progesterone Withdrawal Increases the α4 Subunit of the GABAAReceptor in Male Rats in Association With Anxiety and Altered Pharmacology—A Comparison With Female Rats,”Neuropharmacology, vol. 43, pp. 701-714 (2000).
Gulinello, M., et al., “Anxiogenic Effects of Neurosteroid Exposure: Sex Differences and Altered GABAAReceptor Pharmacology in Adult Rats,”J. Pharmacology and Experimental Therapeutics, vol. 305, No. 2, pp. 541-548 (2003).
Hawkinson, J.E., “Substituted 3β-Phenylethynyl Derivatives of 3α-Hydroxy-5α-pregnan-20-one: Remarkably Potent Neuroactive Steroid Modulators of γ-Aminobutyric AcidAReceptors,”J. Pharmacology and Experimental Therapeutics, vol. 287, No. 1, p. 198-207 (1998).
Hogenkamp, D.J., et al., “Synthesis and in Vitro Activity of 3β- Substituted-3α-Hydroxypregnan-20-ones: Allosteric Modulators of the GABAAReceptor,”J. Med. Chem., vol. 40, pp. 61-72 (1996).
Hsu, F.. et al., “Progesterone Withdrawal Reduces Paired-Pulse Inhibition in Rate Hippocuampus: Dependence on GABAAReceptor α4 Subunit Upregulation,”J. Neurophysiol., vol. 89, pp. 186-198 (2003).
Krogsgaard-Larsen, P., et al., “GABAAAgonists and Partial Agonists: THIP (Gaboxadol) as a Non-Opioid Analgesic and a Novel Type of Hypnotic,”Biochemical Pharmacology, vol. 68, pp. 1573-1580 (2004).
Holt, R.A., et al., “Chronic Treatment with Diazepam or Abecarnil Differently Affects the Expression of GABAAReceptor Subunit mRNAs in the Rat Cortex,”Neuropharmacology, vol. 35, Nos. 9 & 10, pp. 1457-1463 (1996); Abstract only.
Lan, N.C., et al., “Differential Responses of Expressed Recombinant Human Gamma-aminobutyric acidAReceptors to Neurosteroids,”J. Neurochem., vol. 57, No. 5, pp. 1818-1821 (1991) (Abstract Only).
Lee, C., et al., “Effects of Benzodiazepine Receptor Antagonist, Flumazenil, on Antinociceptive and Behavioural Responses to the Elevated Plusmaze in Mice,”Neuropharmacology, vol. 30, No. 12A, pp. 1263-1267 (1991) (Abstract Only).
Medina, J.H., et al., “Overview-Flavonoids: A New Family of Benzodiazepine Receptor Ligands,”Neurochemical Research, vol. 22, No. 4, pp. 419-425 (1997).
Smith, S.S., et al., “Neurosteroid Administration and Withdrawal Alter GABAAReceptor Kinetics in CA1 Hippocampus of Female Rats,”J. Physiol., vol. 567, Pt. 2. pp. 421-436 (2005) (Abstract Only).
Sur, C., et al., “Preferential Coassembly of α4 and δ Subunits of the γ-Aminobutyric AcidAReceptor in Rat Thalamus,”American Society of Pharmacology and Experimental Therapeutics, vol. 56, pp. 110-115 (1998).
Van Miert, A.S., et al., “Appetite-modulating Drugs in Dwarf Goats, With Special Emphasis on Benzodiazepine-induced Hyperphagia and Its Antagonism by Flumazenil and RO 15-3505,”J. Vet. Pharmacol.Ther., vol. 12, No. 2, pp. 147-156 (1989); Abstract only.
Whittemore, E.R., et al., “Pharmacology of the Human Gamma-aminobutyric acidAReceptor Alpha 4 Subunit Expressed inXenopus laevisOocytes,”Mol. Pharmacol., vol. 50, No. 5, pp. 1364-1375 (1996) (Abstract Only).
Wisden, W., et al., “Cloning, Pharmacological Characteristics and Expression Pattern of the Rat GABAAReceptor Alpha 4 Subunit,”FEBS Lett., vol. 289, No. 2, pp. 227-230 (1991) (Abstract Only).
Adkins, C.E., et al., “α4β3δ GABAAReceptors Characterized by Fluorescence Resonance Energy Transfer-derived Measurements of Membrane Potential,”J. Biological Chemistry, vol. 276, No. 42, pp. 38934-38939 (2001).
Akk, G., et al., “Activation of GABA(A) Receptors Containing the alpha4 subunit by GABA and Pentobarbital,”J. Physiol., vol. 556, Part 2, , pp. 387-399 (2004).
Banerjee, P.K., et al., “Alterations in GABAAReceptor α1 and α4 Subunit mRNA Levels in Thalamic Relay Nuclei Following Absence-like Seizures in Rats,”Experimental Neurology, vol. 154, pp. 213-223 (1998).
Biggio, G., et al., “GABAA-receptor Plasticity During Long-Term Exposure to and Withdrawal from Progesterone,”Int. Rev. Neurobiol., vol. 46, pp. 207-241 (2001); Abstract only.
Burt, D.R., “Alpha Subunit Position and GABA Receptor Function,”Science's STKE, No. 270, PE5, pp. 1-2 (2005).
Lovick, T.A., et al., “Changes in GABAAReceptor Subunit Expression in the Midbrain During the Oestrous Cycle in Wistar Rats,”Neuroscience, vol. 131, pp. 397-405 (2005).
Lujan, R., et al., “Glutamate and GABA Receptor Signalling in the Developing Brain,”Neuroscience, vol. 130, pp. 567-580 (2005).
Mody, I., “Distinguishing between GABAAReceptors Responsible for Tonic and Phasic Conductances,”Neurochemical Research, vol. 26, Nos. 8-9, pp. 907-913 (2001).
Porter, B.E., et al., “Heterogenous GABA(A) Receptor Subunit Expression in Pediatric Epilepsy Patients,”Neurobiol. Dis., vol. 18, No. 3, pp. 484-491 (2005) (Abstract Only).
Quirk, G.J., et al., “Inhibition of the Amygdala: Key to Pathological States?,”Ann. N.Y. A

Affiliated with

Also associated with

Rating

Flumazenil for the treatment of cocaine dependency does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Flumazenil for the treatment of cocaine dependency, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Flumazenil for the treatment of cocaine dependency will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3732697